Trademarks and Copyright© The images and information contained in the Site are, to the fullest extent possible, copyrighted and otherwise proprietary. It is the policy of Taro to enforce its intellectual property rights to the fullest extent of the law, including (where applicable) seeking criminal sanctions.

Site Search

News Releases

Receive E-mail Alerts Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now! Search News Release   2013 | 2012 | 2011 | 2010 | 2009 | 2008 Date Title   12/31/09 Taro Reports Voting Results from Its Annual General Meeting 12/18/09 Taro Announces Clinical Trials with T2007, Its Second Proprietary Non-Sedating Barbiturate Drug 12/10/09 Taro Sends Important Update to Shareholders 12/08/09 Taro Sends Letter to Update Shareholders 12/04/09 FDA Approves Initiation of Clinical Studies in the U.S. for T2000, Taro's Proprietary Non-Sedating Barbiturate Compound 12/02/09 Taro Provides Preliminary Third Quarter and Year-to-Date 2009 Financial Results 09/29/09 Taro Files Lawsuit Against Sun in U.S. Federal Court 09/11/09 Taro Announces Postponement of September 13, 2009 Shareholders Meeting 08/10/09 Taro Provides Preliminary First Half 2009 Financial Results 07/27/09 Taro Sues Synerx Pharma, Karalex Pharma and DPT Laboratories for Patent Infringement 07/27/09 Taro Receives FDA Approval for Cetirizine Hydrochloride Tablets (OTC) ANDA 07/15/09 Taro Receives Patent for Ovide(R) 06/11/09 Taro Announces Preliminary Court Approval of Settlement in Securities Lawsuit 06/10/09 Taro and Quinnova Announce Agreement to Co-Promote "Neosalus" and "Cleanse & Treat" in the United States 05/22/09 Taro Provides Preliminary First Quarter 2009 Financial Results 05/22/09 Taro to Restate Financial Results for 2004 and 2005; Revises 2006, 2007 and 2008 Estimated Financial Results 05/21/09 Taro Receives FDA Approval for Sulfacetamide Sodium Topical Suspension ANDA 04/03/09 Taro Receives Final FDA Approval for Carbamazepine Extended-Release Tablets 02/11/09 Taro Receives FDA Approval for Levetiracetam Oral Solution 02/06/09 Taro Receives FDA Warning Letter Following Inspection of Its Canadian Manufacturing Facility 02/05/09 Taro Receives Final FDA Approval for Lamotrigine Chewable Tablets ANDA 02/02/09 Taro Provides Preliminary 2008 Full Year Results 01/28/09 Taro Receives Final FDA Approval for Lamotrigine Tablets ANDA 01/06/09 Sun Refuses to Accept Taro's Offer to Mediate